Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Heart Failure management that’s always there.

So you don’t have to be.


You can’t always be there to manage your heart failure patients. The CardioMEMS™ HF System can give you regular updates on their pulmonary artery pressures to help you optimize GDMT and reduce pressures between office visits.

CardioMEMS HF System
computer

Data-driven care to reduce mortality risk

Remote hemodynamic monitoring with the CardioMEMS HF system enables proactive diuretic titration and helps optimize GDMT therapy to reduce PA pressures.1-4 Lower pressures are associated with reduced heart failure hospitalizations and lower mortality.1,5

Did you know many different types of heart failure patients can benefit from remote hemodynamic monitoring?

View Example Patient Profiles (902KB)

90% of heart failure hospitalizations are due to symptoms of pulmonary congestion.2


Increasing pulmonary artery (PA) pressures can indicate worsening heart failure, weeks before traditional markers like shortness of breath and weight gain. With remote access to precise hemodynamic data, you can make proactive medication adjustments and manage fluid levels to help prevent decompensation.1

cardiomems wedge chart

Adamson PB. Current Heart Failure Rep. 2009

See if your heart failure patients are indicated for the CardioMEMS HF System.

Take the Patient Indication Quiz

Reduced PA pressures can lead to reduced heart failure mortality3 and improved quality of life.1


Hemodynamic monitoring of PA pressure allows for proactive changes to medications that can reduce mortality for HFrEF patients by 25%.3

Small changes in PA pressures can make a difference in mortality.4 In the first 6 months post-implant of the CardioMEMS HF System, results showed:
 

Every 1 mmHG reduction in diastolic PA Pressure (PAP) reduces mortality by 3%4

heart icon

Patients with PA pressure reduction of ≥2 mmHg within the first 6 months post-implant have a decrease in mortality of 15% at 2 years.4

down 15%
See the Publication

In MONITOR-HF, a randomized control trial, remote hemodynamic management with the CardioMEMS HF System showed:

44% reduction in heart failure hospitalizations1

down 44%

7pt improvement in KCCQ scores1

up 7 points
View Clinical Evidence

The CardioMEMS HF System is the only PA pressure monitor proven to reduce overall PA pressures6-14

The CardioMEMS HF System has been proven safe, reliable,1 and has helped over 50,00015 patients and their care teams manage heart failure. Over 10 years of experience and three randomized control trials have shown that managing heart failure with CardioMEMS and reducing PA pressures slows the progression of heart failure.1,6,15

 

References

  1. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial [published correction appears in The Lancet. 2023;401(10394):2112]. The Lancet. 2023;401(10394):2113-2123. doi:10.1016/S0140-6736(23)00923-6.
  2. Adams KF Jr, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005 Feb;149(2):209-16.
  3. Lindenfeld J, Costanzo MR, Zile MR, et al. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83(6):682-694. doi:10.1016/j.jacc.2023.11.030.
  4. Zile MR, Abraham WT, Stevenson LW, et al. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure. Circ Heart Fail. Published online April 14, 2025. doi:10.1161/CIRCHEARTFAILURE.124.012754.
  5. Zalawadiya S, Abraham J, Rathman L, et al. Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure. JACC Heart Fail. 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589.
  6. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. The Lancet. 2011;377(9766):658-66.
  7. Angermann C, Assmus B, Anker SD, et al. Pulmonary-arterypressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). European Journal of Heart Failure. 2020;22(10):1891-901.
  8.  Shavelle D, Desai A, Abraham W, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. 2020;13(8):229- 38.
  9. Heywood JT, Zalawadiya S, Bourge RC, et al; CardioMEMS Post-Approval Study Investigators. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. Journal of Cardiac Failure. 2023;29(1):56-66.
  10. Lindenfeld J, Zile MR, Desai AS, et al. Hemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. The Lancet. 2021;398:991-1001.
  11. Mehra M, Costanzo MR, Zile M, et al; GUIDE-HF Trial Investigators. Primary results of the prospective single arm trial of hemodynamic-guided management of heart failure (GUIDE- HF). Presented at: Heart Failure Society of America (HFSA) Conference; October 2023; Cleveland, OH
  12. Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based management of PA pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017;135:1509-17.
  13. Cowie MR, Flett A, Cowburn P, et al. Real-world evidence in a national health service: results of the UK CardioMEMS HF System post-market study. ESC Heart Failure. 2021;9(1):48-56.
  14. Guichard JL, Bonno EL, Nassif ME, et al. Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure: Results of thePROACTIVE-HF Trial. JACC: Heart Failure,  2022;S2213- 1779(24)00485- 2. Advance online publication. https://doi.org/10.1016/j.jchf.2024.05.017.
  15. Abbott Data on File

MAT-2505156 v3.0